Cutera Announces Japanese Ministry of Health Approval for Solera Titan(TM) Infrared Light System


TOKYO, Sept. 3, 2011 (GLOBE NEWSWIRE) -- Cutera, Inc. (Nasdaq:CUTR), a leading provider of laser and light-based aesthetic systems for practitioners worldwide, today announced that Japan's Ministry of Health Labor and Welfare ("MHLW") approved the Solera Titan for marketing and distribution. Featuring a unique infrared light, Solera Titan delivers bulk heating deep into the skin's dermis.

Chris West, Vice President, Pacific Rim for Cutera, said, "Solera Titan has been available in Europe since 2005 for treating wrinkles and improving the overall appearance of skin. We are pleased that, with the recent MHLW approval, Titan is now widely available to the over 12,000 general hospitals and clinics throughout Japan, in addition to physicians in private practice."

"With many peer reviewed, published academic papers, Titan has a documented history of producing healthy collagen (Type I) and viable elastin in the skin's dermal layer," said Yohei Tanaka, MD, PhD, Associate Clinical Professor for Plastic Surgery, Shinshu University in Nagano, Japan.Dr.Tanaka, a leading plastic surgeon in Japan, is an expert in infrared light-based procedures with significant contributions to the base of peer-reviewed, published research on the Titan procedure. "I am very excited that this technology is now approved in Japan. Patients experience no downtime and are extremely pleased with the outcome."

About Cutera, Inc.

Brisbane, California-based Cutera is a leading provider of laser and other light-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit http://www.cutera.com/">www.cutera.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995: Specifically, statements concerning the features, effectiveness, treatable conditions, and the potential market size for Cutera's product, are forward-looking statements within the meaning of the Safe Harbor. Such forward-looking statements are subject to risks and uncertainties and may be affected by various factors that may cause actual results to differ materially from those in the forward-looking statements and those other factors described in the section entitled, "Risk Factors," in Cutera's most recent Form 10-Q as filed with the Securities and Exchange Commission on August 1, 2011. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.



            

Contact Data